Loading organizations...
Arnatar Therapeutics is a biopharmaceutical company based in San Diego, California, that develops novel RNA therapeutics targeting cardiometabolic, liver, central nervous system, and rare kidney diseases. Founded in 2021 by Dr. Xuehai Liang and Dr. Yanfeng Wang, the preclinical biotechnology firm utilizes its proprietary DARGER platform, which combines small interfering RNA for targeted gene silencing with upregulating antisense oligonucleotides to restore gene expression. In October 2024, the innovative enterprise emerged from stealth mode after securing $52 million in Series A funding to advance its preclinical and clinical drug pipeline. This major financing round was backed by prominent venture capital investors, including Eight Roads, 3E Bioventures, F-Prime Capital, and Apricot Capital. Furthermore, the organization's lead therapeutic candidate, ART4, recently received orphan drug and rare pediatric disease designations from the FDA for the treatment of Alagille syndrome.
Arnatar Therapeutics has raised $52.0M across 1 funding round.
Arnatar Therapeutics has raised $52.0M in total across 1 funding round.
Arnatar Therapeutics has raised $52.0M across 1 funding round. Most recently, it raised $52.0M Series A in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 25, 2025 | $52M Series A | 3E Bioventures Capital, Eight Roads Ventures | Chuanhua Capital, F Prime Capital, Gaorong Capital, Hongsheng Capital, NEW Alliance Capital, Yijing Capital | Announced |
Arnatar Therapeutics has raised $52.0M in total across 1 funding round.
Arnatar Therapeutics's investors include 3E Bioventures Capital, Eight Roads Ventures, Chuanhua Capital, F-Prime Capital, Gaorong Capital, Hongsheng Capital, New Alliance Capital, Yijing Capital.
